CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Metabolic reprogramming driven by Ant2 deficiency augments T Cell function and anti-tumor immunity in mice.
Metabolic reprogramming driven by Ant2 deficiency augments T Cell function and anti-tumor immunity in mice.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
T细胞活化需要NAD+生成大幅增加,往往超出氧化磷酸化(OXPHOS)的能力。为研究T细胞如何适应这一代谢挑战,我们构建了T细胞特异性ADP/ATP转位酶-2敲除(Ant2-/-)小鼠。Ant2是介导线粒体与细胞质之间ADP/ATP交换的关键蛋白,其缺失通过限制ATP合酶活性诱导OXPHOS受限,从而阻碍NAD+再生。有趣的是,与野生型对照相比,Ant2-/-初始T细胞表现出增强的活化、增殖和效应功能。代谢谱分析显示,这些T细胞采用了一种活化样代谢程序,伴有线粒体生物发生和合成代谢增加。最后,在野生型T细胞中药理学抑制ANT可重现Ant2-/-表型,并改善小鼠模型中的过继性T细胞癌症治疗。因此,我们的研究结果表明,Ant2缺陷T细胞绕过了活化所需的典型代谢重编程,导致T细胞功能增强,并凸显了靶向ANT用于免疫调节的治疗潜力。
T cell activation requires a substantial increase in NAD + production, often exceeding the capacity of oxidative phosphorylation (OXPHOS). To investigate how T cells adapt to this metabolic challenge, we generate T cell-specific ADP/ATP translocase-2 knockout (Ant2 -/- ) mice. Loss of Ant2, a crucial protein mediating ADP/ATP exchange between mitochondria and cytoplasm, induces OXPHOS restriction by limiting ATP synthase activity, thereby impeding NAD + regeneration.
Interestingly, Ant2 -/- naïve T cells exhibit enhanced activation, proliferation and effector functions compared to wild-type controls. Metabolic profiling reveals that these T cells adopt an activated-like metabolic program with increased mitobiogenesis and anabolism. Lastly, pharmacological inhibition of ANT in wild-type T cells recapitulates the Ant2 -/- phenotype and improves adoptive T cell therapy of cancer in mouse models.
Our findings thus suggest that Ant2-deficient T cells bypass the typical metabolic reprogramming required for activation, leading to enhanced T cell function and highlighting the therapeutic potential of targeting ANT for immune modulation.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。